J&J reports 89% response rate in bladder cancer drug trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Wall Street climbs as Broadcom and other chipmakers rally
- Oil prices little changed as Saudi cuts prices, OPEC+ boosts target
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- Wall Street climbs as Broadcom and other chipmakers rally
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
March 13, 2026 12:35 PM EDTData presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the potential to be the first targeted treatment for earlystage bladder cancer
RARITAN, N.J., March 13, 2026 /PRNewswire/ --Â Johnson & Johnson (NYSE: JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS)... More
